| Original language | English |
|---|---|
| Pages (from-to) | 293-294 |
| Number of pages | 2 |
| Journal | JACC. Heart Failure |
| Volume | 10 |
| Issue number | 4 |
| DOIs |
|
| Publication status | Published - 1 Apr 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: JACC. Heart Failure, Vol. 10, No. 4, 01.04.2022, p. 293-294.
Research output: Contribution to journal › Comment/Letter to the editor › Academic
TY - JOUR
T1 - Reply
T2 - A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of HFrEF
AU - Tromp, Jasper
AU - Ouwerkerk, Wouter
AU - Lam, Carolyn S. P.
AU - Voors, Adriaan A.
N1 - Funding Information: Dr Tromp is supported by the National University of Singapore start-up grant, the tier 1 grant from the Ministry of Education, and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai. Dr Voors has received research support and/or has been a consultant for Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim, Cytokinetics, Merck, Myokardia, Novo Nordisk, Novartis, and Roche Diagnostics. Dr Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. Dr Ouwerkerk has reported that he has no relationships relevant to the contents of this paper to disclose. Funding Information: Dr Tromp is supported by the National University of Singapore start-up grant, the tier 1 grant from the Ministry of Education, and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi-Sankyo, Boehringer Ingelheim, Roche diagnostics and Us2.ai. Dr Voors has received research support and/or has been a consultant for Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim, Cytokinetics, Merck, Myokardia, Novo Nordisk, Novartis, and Roche Diagnostics. Dr Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott, Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, EchoNous Inc, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. Dr Ouwerkerk has reported that he has no relationships relevant to the contents of this paper to disclose.
PY - 2022/4/1
Y1 - 2022/4/1
UR - http://www.scopus.com/inward/record.url?scp=85126658534&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jchf.2022.01.016
DO - https://doi.org/10.1016/j.jchf.2022.01.016
M3 - Comment/Letter to the editor
C2 - 35361454
SN - 2213-1779
VL - 10
SP - 293
EP - 294
JO - JACC. Heart Failure
JF - JACC. Heart Failure
IS - 4
ER -